Evidence map›Paper›PMID 40453098›Full record

ArticleFrontiers in immunology2025

First successful treatment of epidermolytic Ichthyosis with Vunakizumab: A Case Report.

Wenjie Cheng, Chaolan Pan, Zhe Sun, Peiyi Sun, Jiawen Li, Zhirong Yao, Xiaoxiao Wang, Jia Zhang

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wenjie Cheng *Dermatology Center, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Chaolan Pan *Dermatology Center, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Zhe Sun *Dermatology Center, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Peiyi SunDermatology Center, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Jiawen LiDermatology Center, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Zhirong YaoDermatology Center, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Xiaoxiao WangDermatology Center, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Jia ZhangDermatology Center, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ichthyoses, a group of skin cornification disorders caused by protein and lipid abnormalities that disrupt epidermal functions, are mainly characterized by generalized scaling. This study is the first to report the use of Vunakizumab, China's first self-developed anti-IL-17A monoclonal antibody, in treating ichthyosis. We presented a case of a 4-year-old boy with epidermolytic ichthyosis (EI) due to a

Indexed as

Antibodies, Monoclonal, HumanizedHyperkeratosis, EpidermolyticChild, PreschoolHumansInterleukin-17Keratin-1MaleMutationTreatment OutcomeAntibodies, Monoclonal, HumanizedInterleukin-17Keratin-1KRT1 protein, humanepidermal barrier dysfunctionichthyosisimmunotherapyKRT1 gene mutationVunakizumab

Identifiers

PMID40453098
PMCPMC12122345

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.